Hereditary Autoinflammatory Diseases: Clinical Trials

14 trials for Hereditary Autoinflammatory Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 2 terminated, 1 enrolling by invitation. 14 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Completed 7, Recruiting 2, Terminated 2, Enrolling by invitation 1, Unknown 1, Withdrawn 1
Phase 24Completed 2, Terminated 1, Withdrawn 1

Follow Hereditary Autoinflammatory Diseases: new trials by email Literature Review of Hereditary Autoinflammatory Diseases trials Research Report on Hereditary Autoinflammatory Diseases

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of JTE-162 in Subjects With Cryopyrin-Associated Periodic Syndrome (CAPS)
JTE-162 - Cryopyrin-associated Periodic Syndromes (CAPS)
Phase 1CompletedAkros Pharma Inc.52026-02-022026-10-09
Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load
124I AT-01 - Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Phase 1RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)302025-09-102026-05-19
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1Enrolling by invitationChugai Pharmaceutical1442024-12-092026-07-17
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1RecruitingChugai Pharmaceutical1442024-08-192026-07-22
Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334
IZD334, Placebos - Healthy Volunteers, Cryopyrin Associated Periodic Syndrome
Phase 1CompletedInflazome UK Ltd642019-09-132020-03-02
Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)
Canakinumab - Periodic Fever
Phase 1UnknownRabin Medical Center102016-08-012018-09-04
A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study
HL2351, Kineret(Anakinra) - Healthy Volunteers
Phase 1CompletedHandok Inc.582014-05-012015-10-06
Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study
Intravitreal Infliximab - Behçet's Disease, Uveitis
Phase 1 / Phase 2CompletedCairo University202013-01-012015-12-03
Anakinra for Behcet s Disease
Anakinra - Autoimmune Connective Tissue Disorder, Immune System Diseases
Phase 1 / Phase 2CompletedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)62011-09-012017-05-12
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
XOMA 052 - Muckle Wells Syndrome, Autoinflammatory
Phase 1 / Phase 2WithdrawnNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2010-08-272017-07-02
Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) Patients
colchicine sprinkle capsules - Familial Mediterranean Fever
Phase 1CompletedMutual Pharmaceutical Company, Inc.752010-08-012012-01-10
Stem Cell Transplantation in Ocular Lesions of Behcet's Disease
Autologous Stem Cell Transplantation - Retinitis, Behcet's Syndrome
Phase 1TerminatedTehran University of Medical Sciences52007-12-012015-11-10
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Kineret (anakinra) - Familial Cold Urticaria
Phase 1CompletedNova Scotia Health Authority82005-09-012022-11-08
Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease
anakinra - Nervous System Malformations, Arthropathy, Neurogenic
Phase 1 / Phase 2TerminatedNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)432003-09-012016-12-01

Narrower conditions

Cryopyrin-Associated Periodic Syndromes (7)  ·  Behcet Syndrome (6)  ·  Antiphospholipid Syndrome (2)  ·  Dermatomyositis (2)  ·  Papilledema (2)  ·  Pemphigoid, Bullous (2)  ·  Purpura, Thrombocytopenic, Idiopathic (2)  ·  Uveitis (2)  ·  Amyloidosis (1)  ·  Arthritis, Rheumatoid (1)  ·  Arthropathy, Neurogenic (1)  ·  Congenital Abnormalities (1)  ·  Familial Mediterranean Fever (1)  ·  Immune System Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Genetic Diseases, Inborn (14)  ·  Skin Diseases (13)  ·  Skin Diseases, Genetic (13)  ·  Skin and Connective Tissue Diseases (13)  ·  Skin Diseases, Vascular (12)  ·  Immune System Diseases (9)  ·  Pathologic Processes (9)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Chronic Disease (7)  ·  Chronic Inducible Urticaria (7)  ·  Chronic Urticaria (7)  ·  Cold Urticaria (7)  ·  Disease Attributes (7)

Interventions

Interleukin 1 Receptor Antagonist Protein (4)  ·  canakinumab (1)  ·  gevokizumab (1)

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3)  ·  Chugai Pharmaceutical (2)  ·  Akros Pharma Inc. (1)  ·  Cairo University (1)  ·  Handok Inc. (1)  ·  Inflazome UK Ltd (1)  ·  Mutual Pharmaceutical Company, Inc. (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Nova Scotia Health Authority (1)  ·  Rabin Medical Center (1)  ·  Tehran University of Medical Sciences (1)

Countries

United States (6)  ·  Canada (4)  ·  Australia (3)  ·  Turkey (Türkiye) (3)  ·  Austria (2)  ·  Bulgaria (2)  ·  Croatia (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  Netherlands (2)

Top investigators

Behrouz Nikbin, MD (1)  ·  Fereydoun Davatchi, MD (1)  ·  Hormoz Shams, MD (1)  ·  Hyeong Ki Lee, Professor (1)  ·  Jason Lickliter, MBBS, PhD (1)  ·  Liora Harel, MD (1)  ·  Mahmoud Soliman, MD PhD (1)  ·  Matthew Davis, MD (1)  ·  Peter C Grayson, M.D. (1)  ·  Raphaela T Goldbach-Mansky, M.D. (1)  ·  Sara Alehashemi, M.D. (1)

Results publications

PMID 16899778, PMID 22294344, PMID 23773637, PMID 25223501, PMID 27143789, PMID 28118536, PMID 28335798

NIH funding

ZIAAR041138-08 (1)